XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2024
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lynparza$292 $275 
Alliance revenue - Koselugo38 23 
Total alliance revenue$330 $298 
Cost of sales (1)
82 70 
Selling, general and administrative39 47 
Research and development20 21 
($ in millions)March 31, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$334 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
617 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Lenvima$255 $232 
Cost of sales (1)
60 126 
Selling, general and administrative39 51 
Research and development8 39 
($ in millions)March 31, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$255 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
125 125 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Alliance revenue - Adempas/Verquvo$98 $99 
Net sales of Adempas recorded by Merck70 59 
Net sales of Verquvo recorded by Merck5 7 
Total sales$173 $165 
Cost of sales (1)
62 57 
Selling, general and administrative33 33 
Research and development28 25 
($ in millions)March 31, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$155 $156 
Payables to Bayer included in Accrued and other current liabilities
74 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Net sales of Lagevrio recorded by Merck
$350 $392 
Cost of sales (1)
191 221 
Selling, general and administrative
16 27 
Research and development
(5)16 
($ in millions)March 31, 2024December 31, 2023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$160 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $3 $— 
Research and development
69 — 
($ in millions)March 31, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$817 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20242023
Selling, general and administrative $2 $1 
Research and development
69 26 
($ in millions)March 31, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$72 $63